Video 1_Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study.mp4 by Vladimir Gabai (38129)

“…Traditional OA management consist of non-steroidal anti-inflammatory drugs and remains challenging because of significant side effects, thus there is an urgent need for new effective and safe therapeutics for OA.…”

DataSheet1_An observational study of lower limb muscle imbalance assessment and gait analysis of badminton players.docx by Ping Huang (30439)

“…Lower limb muscle imbalance can cause gait abnormalities and increase the risk of muscle injury or decreased performance in significantly asymmetrical situations. …”

Summary of this study. by Satoshi Hara (539722)

“…Panels showing significant differences are highlighted. The arrows indicate increased or decreased. …”

Investigation of changes in the choice reaction time with levodopa in patients with Parkinson’s disease by Halil Onder (10368032)

“…The comparative analyses between medication-off and -on states revealed that the MDS-UPDRS-3 scores decreased significantly during the medication-on states (<i>p</i> < 0.001, d = 1.09). …”

Potential benefits and neural correlates of adjunctive acupuncture therapyin unilateral stroke rehabilitation by Jia Fan (20107030)

“…On the Chinese side, Drs Zhang, Ren, Lu, and Zhu acquire magnetic resonance imaging (MRI) and physical data. …”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p>Methods<p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p>Methods<p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p>Methods<p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p>Methods<p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p>Methods<p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.…”

Supplementary file 1_Does body weight support improve neural and biomechanical measures during treadmill gait in children with unilateral cerebral palsy?.docx by Rajit Banerjee (22481089)

“…</p>Results<p>Minimal or no group differences or BWS effects were found for synergy number, structure or Walk-DMC, whereas the Gait Deviation Index (GDI) showed a significant interaction with 20% BWS where the dominant side in CP improved with 20% BWS while both sides in TD worsened. …”

Table 1_Sensory reweighting for postural stability in individuals with low vision and blindness: balance adaptation and muscle co-contraction.xlsx by Yue Li (102191)

“…The rectus abdominis/erector spinae ratio decreased significantly with somatosensory deprivation, whereas the gastrocnemius/tibialis anterior co-contraction index increased significantly under both visual and somatosensory deprivation, with higher co-contraction observed in both low-vision and blind participants.…”

Spectral slope analysis. by Anika T. Löwe (19924021)

“…<p>A: The spectral slope significantly decreased from Wake to N1 to N2, as expected. …”

Data Sheet 1_Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation.zip by Raheem F. H. Al Aameri (14951800)

“…<p>Cisplatin is a chemotherapy drug used to treat different solid tumors, including ovarian, bladder, lung, and head and neck cancers. One of its significant side effects is ototoxicity, especially when high doses are required. …”

The 16S rRNA sequencing raw data for the study titled Effects of high-dose glucocorticoids on gut microbiota in the treatment of Graves' ophthalmopathy by Xinhuan Su (21147710)

“…The short chain fatty acids (SCFAs)-producing ability in GO patients’ gut after high-dose GCs administration was significantly decreased. The 5-hydroxytryptamine (5-HT) levels significantly increased in gut of GO patients after administering high-dose GCs. …”

Data Sheet 1_Efficacy and safety of topical minocycline preparations for papulopustular rosacea: a systematic review and meta-analysis.pdf by Awadh Alamri (20970752)

“…Topical minocycline allow the delivery of high concentrations of the medication to the skin while decreasing systemic exposure thereby evading side effects (Jones et al., 2021, Webster et al., 2020). …”

Table 1_Saikosaponin A induces cellular senescence in triple-negative breast cancer by inhibiting the PI3K/Akt signalling pathway.docx by Yingchao Wu (2870927)

“…Existing therapeutic agents are generally accompanied by significant side effects. Here, we highlight Saikosaponin A (SSA), a promising natural metabolite characterized by low toxicity, demonstrating significant efficacy against breast cancer through the induction of cellular senescence.…”

Supplementary Material for: Successful Management of Post-Thymectomy Pure Red Cell Aplasia with Rituximab: A Case Report by Abdulgayoom M. (17726475)

“…Abstract Background: Pure red cell aplasia (PRCA) is a rare cause of anemia characterized by decreased red blood cell production, often associated with thymomas. …”

Data Sheet 2_Triterpenes in breast cancer: a systematic review of preclinical evidence in rodents.xlsx by Alexandra Prodea (22617710)

“…Introduction<p>Breast cancer poses a significant health problem for women worldwide due to late-stage diagnosis, toxicity of standard therapy and drug resistance. …”

Data Sheet 1_Saikosaponin A induces cellular senescence in triple-negative breast cancer by inhibiting the PI3K/Akt signalling pathway.docx by Yingchao Wu (2870927)

“…Existing therapeutic agents are generally accompanied by significant side effects. Here, we highlight Saikosaponin A (SSA), a promising natural metabolite characterized by low toxicity, demonstrating significant efficacy against breast cancer through the induction of cellular senescence.…”